Ozette
3 known investors
Ozette provides AI-enabled clinical biomarker analysis from spectral cytometry data for pharmaceutical trials and research, offering both a managed lab service and a self-serve software platform. The company serves clinical development teams, drug developers, and academic labs requiring reproducible biomarker endpoints and immune cell characterization.
Investors · 3
In the news
- Seattle biotech Ozette raises $26M round led by Madrona - Puget Sound Business Journalbizjournals.com · 2022
- Ozette Raises $26M in Series A Fundingfinsmes.com · 2022
- Ozette Announces $26MM in Series A Funding for AI-Powered Single-Cell Immune Discovery Technology that Accelerates Therapeutics Across Research and Development - BioSpacebiospace.com · 2022
- Ozette raises $6 million for immune system-monitoring tech | VentureBeatventurebeat.com · 2021
- Fred Hutch biotech spinout Ozette raises $6M from Madrona, AI2, Vulcan – GeekWiregeekwire.com · 2021
- Ozette raises $6M seed funding to accelerate breakthroughs in treating diseases using its AI-powered immune monitoring platform - Tech Startupstechstartups.com · 2021